Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies

US9388221B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• John T. Schiller · Silver Spring, US
• Diana V. Pastrana · McLean, US
• Richard Roden · Severna Park, US
• Ratish Gambhira · Baltimore, US
• Douglas R. Lowy · Washington, US

Key dates

• Filing date: Feb 21, 2013
• Grant date: Jul 12, 2016
• Expiry date: Feb 21, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/20034
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide.